706 related articles for article (PubMed ID: 23324563)
1. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
Gossger N; Snape MD; Yu LM; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Becker B; Kieninger D; Prymula R; Dull P; Ypma E; Toneatto D; Kimura A; Pollard AJ;
JAMA; 2012 Feb; 307(6):573-82. PubMed ID: 22318278
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.
Chiu NC; Huang LM; Willemsen A; Bhusal C; Arora AK; Reynoso Mojares Z; Toneatto D
Hum Vaccin Immunother; 2018 May; 14(5):1075-1083. PubMed ID: 29337653
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
[TBL] [Abstract][Full Text] [Related]
7. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
Carter NJ
BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
[TBL] [Abstract][Full Text] [Related]
8. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M
Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).
Esposito S; Prymula R; Zuccotti GV; Xie F; Barone M; Dull PM; Toneatto D
Hum Vaccin Immunother; 2014; 10(7):2005-14. PubMed ID: 25424810
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial.
P Safadi MA; Martinon-Torres F; Weckx LY; Moreira ED; da Fonseca Lima EJ; Mensi I; Calabresi M; Toneatto D
Vaccine; 2017 Apr; 35(16):2052-2059. PubMed ID: 28318767
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Marshall HS; Vesikari T; Richmond PC; Wysocki J; Szenborn L; Beeslaar J; Maguire JD; Balmer P; O'Neill R; Anderson AS; Prégaldien JL; Maansson R; Jiang HQ; Perez JL
Lancet Infect Dis; 2023 Jan; 23(1):103-116. PubMed ID: 36087588
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
